Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LADI study of adalimumab interval lengthening in quiescent Crohn's disease
NL-OMON47881Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in Crohn's disease (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Cumulative incidence of persistent flares. Started May 2017; status: recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON47881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47881.